Based on the current data, the improvements due to pre-symptomatic butyrate treatmentinclude improving the intestinal barriers, correcting dysbiosis, restoring Paneth cells, andreducing aggregation of the G93A-SOD1 mutated protein in ALS mice, thus slowing down theprogression of disease. Here, SOD1 is linked to amyotrophic lateral sclerosis.